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were assessed after the first course of treatment for each 
patient and each subsequent cohort was enrolled once each 
subject had completed the first course of treatment and its 
4-week follow-up period. The occurrence of adverse events 
(AEs) and response to treatment were assessed after the 
induction course and then periodically.
Results During the study, no DLTs were observed. Only 
5 grade 1 and 2 AEs, which occurred in 4 patients were 
considered as possibly related to BC-819. The best tumor 
response seen was stable disease. Median survivals of 
3.2, 5.3 and 6.5 months were observed for the 60, 120 and 
240 mg cohorts, respectively.
Conclusions BC-819 can be considered safe and well tol-
erated in intraperitoneal doses up to 240 mg. Hybridization 
of intraperitoneal chemotherapy with the biological treat-
ment of BC-819 should be further evaluated in phase 2 and 
3 studies.
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Introduction
Ovarian cancer is a biologically aggressive cancer with 
exceptionally high mortality rate, making it the fifth most 
common causes of death from malignancy in women [1]. In 
the United States, ovarian cancer is the seventh most com-
mon cancer in women accounting for almost one-third of 
invasive malignancies of the female genital organs and has 
remained the leading cause of death from gynecological 
cancers with nearly 22,000 new cases and 15,460 deaths in 
2011 [1].
The majority of patients with ovarian cancer will have 
advanced-stage disease at initial diagnosis and this is 
Abstract 
Background H19 is a paternally imprinted, oncofetal gene 
expressed in various embryonic tissues and in 85% of the 
ovarian tumors. H19-DTA (BC-819) is a DNA plasmid that 
drives the expression of the diphtheria toxin gene under the 
regulation of the H19 promoter sequence and therefore is a 
potential treatment for various tumors that overexpress the 
H19 gene, among them—ovarian cancer.
Objective To assess the safety and efficacy of intra-peri-
toneal (IP) instillations of H19-DTA (BC-819) plasmid in 
treating ovarian/peritoneal cancer patients with advanced 
recurrent disease.
Methods A phase 1–2A multi-centric trial included 14 
eligible patients who were either platinum-refractory or 
platinum-resistant with positive H19 expression. Patients 
were treated IP with escalating weekly doses of BC-819 for 
a maximum of 6–9 weeks. Dose-limiting toxicities (DLT) 
 * Eli Raveh 
 Eli.Raveh@mail.huji.ac.il
1 Department of Obstetrics and Gynecology Carmel Medical 
Center, The Rappaport Faculty of Medicine, Technion, Haifa, 
Israel
2 Sharett Institute of Oncology, Hadassah-Hebrew University 
Medical Center, Jerusalem, Israel
3 Department of Obstetrics and Gynecology, The Edith 
Wolfson Medical Center-Holon, Sackler School of Medicine, 
Tel-Aviv University, Tel-Aviv, Israel
4 Department of Gynecology and Obstetrics, Meir Hospital 
Kfar-Saba, Sackler School of Medicine, Tel-Aviv University, 
Tel-Aviv, Israel
5 BioCancell Therapeutics Ltd, Jerusalem, Israel
6 The Department of Biological Chemistry, Institute of Life 
Sciences, The Hebrew University of Jerusalem, Jerusalem, 
Israel
752 Arch Gynecol Obstet (2017) 295:751–761
1 3
intimately linked with the poor prognosis of the disease [2, 
3].
Most patients with advanced stage disease will experi-
ence relapse, and only 20–25% of patients can be expected 
to be long-term survivors, despite a good response to pri-
mary treatment [4].
The primary intervention for advanced stage ovarian 
cancer is debulking surgery followed by chemotherapy 
with platinum-based analogues and paclitaxel and/or neo-
adjuvant chemotherapy followed by debulking surgery and 
adjuvant chemotherapy [3, 5–7].
Despite the improved median overall survival in patients 
with such chemotherapy regimens, relapse still occurs 
in the majority of those with advanced disease, and only 
10–30 % of such patients have long-term survival [4–6, 8, 
9].
Ovarian cancer is a disease that initially spreads through-
out the abdominal cavity, although in some cases a pleural 
effusion or extraperitoneal spread can be detected [10]. The 
mortality associated with ovarian cancer is primarily due 
to dissemination of the disease within the peritoneal cavity 
due to the absence of early diagnostic symptoms. When the 
peritoneal cavity is involved, conventional therapies such as 
surgery and chemotherapy in most of the cases fail to pro-
vide long-term cure [11].
Three randomized prospective studies of IP chemother-
apy [12–14] documented an advantage in overall survival 
for patients receiving chemotherapy in the IP arm, and 
despite a significant short-term quality of life deteriora-
tion in the IP, these prospective studies suggested a pos-
sible advantage for tumor lysis through this drug delivery 
route.
H19 is a paternally imprinted, oncofetal gene that 
encodes a ribonucleic acid (RNA), with no protein prod-
uct, which acts as a “riboregulator”. It is upregulated in 
tumor cells and promotes cancer progression, angiogenesis, 
and metastasis [15–17]. BC-819 (formerly, DTA-H19) is 
a double-stranded deoxyribonucleic acid (DNA) plasmid, 
4,560 base pairs (bp) in length, carrying the gene for the 
diphtheria toxin A (DT-A) chain under the regulation of the 
814  bp 5′ flanking region of the H19 promoter sequence. 
DT-A chain expression is triggered by the presence of tran-
scription factors that are upregulated in tumor cells. The 
selective initiation of toxin expression results in selective 
tumor cell destruction via inhibition of protein synthesis in 
the tumor cell, enabling highly targeted cancer treatment. 
This therapy is determined by tumor tissue/cell screening 
for H19 RNA expression in order to select the appropriate 
patient population and to ensure success of treatment.
Previous non-clinical studies in animals showed that 
BC-819 inhibited tumor cell growth in a heterotopic nude 
mouse ovarian cancer model [18] and slowed tumor cell 
growth in a nude mouse ovarian cancer ascites model 
(unpublished data). In humans, BC-819 was administered 
in bladder [19] and pancreatic [20] carcinoma and to an 
ovarian cancer patient under a compassionate protocol 
[21].
The intraperitoneal [IP] administration route allows 
reduced systemic exposure and its possible toxic effects 
[22] together with higher availability of the drug over time. 
The IP administration of BC-819 has the potential to reach 
ascites tumor cells, deliver its intracellular toxin and selec-
tively destroy tumor cells without targeting normal tissues, 
and thus helping to control this aspect of ovarian cancer.
The aim of the current study was to determine the 
safety, tolerability, PK, preliminary efficacy and quality 
of life (QoL) of BC-819 administered IP in subjects with 
advanced stage ovarian cancer. The study’s primary end-
point was to assess the DLTs of BC-819 and its maximum 
tolerated dose (MTD) in this patient population.
Study design
This was a Phase 1/2a, open label, dose-escalation, repeat 
dose study in 14 subjects with recurrent, platinum-resistant 
advanced stage ovarian cancer or primary peritoneal car-
cinoma. Following a screening period of up to 6 weeks, 
subjects were enrolled in 3 cohorts. Subjects in the first 
cohort received, IP, an absolute dose of 60 mg of BC-819 
and sequential cohorts received escalating doses of BC-819 
(120  mg in the second cohort, and 240  mg in the third 
cohort, absolute doses).
The dose and schedule of BC-819 administration was 
based in part on preclinical animal-efficacy studies, in 
which it was shown that intraperitoneal injection of the 
plasmid significantly reduced the growth rate of ovarian 
carcinoma and reduces the amount if ascites accumulation 
as compared with the control group in an orthotopic animal 
model for ovarian cancer.
BC-819 was supplied as a frozen liquid formulated to 
contain 4 mg/mL of plasmid DNA. Vials were thawed and 
diluted to a total volume of 500 mL with sterile 0.9% pre-
servative-free saline. BC-819 was administered intraperi-
toneally via a fully implantable port attached to a single-
lumen catheter which was placed SC on the left inferior 
thorax at the mid-clavicular line above ribs number 9–10. 
Subjects were assessed by CT or positron emission tomog-
raphy/CT at screening and in the final week of every treat-
ment course follow-up. No additional surgeries (secondary 
debulking nor palliative surgery) were performed in any of 
the patients along the study period.




Patients were recruited from 4 gynecological oncol-
ogy centers in Israel after the protocol was reviewed and 
approved by the research ethics committee of each par-
ticipating site. Written informed consent was obtained 
from each patient at the time of enrollment. After obtain-
ing informed consent, patients were screened over a week 
period for medical history, prior cancer treatments and 
medication use, physical examination, electrocardiogram, 
hematology, blood chemistries, coagulation markers, tumor 
markers, urinalysis, Karnofsky performance status, vital 
signs, height and weight, tumor biopsy(/ies) for histopathol-
ogy and ISH (in situ hybridization) for H19 gene expres-
sion, radiological assessments including chest X-ray, chest, 
abdominal and pelvic computerized tomography (CT), and/
or abdominal CT/positron emission tomography, and other 
scans as clinically indicated (magnetic resonance imaging, 
brain CT, bone scan). Subjects were assigned to cohorts 
sequentially when determined to be eligible for the study. 
The first eight eligible subjects were assigned to cohort no. 
1; 60  mg IP BC-819 weekly for 3 weeks, one week rest, 
then repeat for 2 more courses, except for two patients that 
were treated according to a revised protocol, due to FDA 
recommendation; those two patients were treated weekly 
for 3 weeks, followed by 4  weeks rest and safety follow-
up for DLTs (instead of 1 week safety follow-up), and then 
repeating one additional course. The FDA recommenda-
tions arose in a discussion following what was analyzed 
as drug-unrelated deaths that occurred during the study, 
and intended to change the study design and, respectively, 
revise the protocol so as to allow completion of treatment 
courses and make it more consistent with a Phase 1 safety 
study design. Once a subject had completed one course of 
treatment with 4 weeks of follow-up with no progressive 
disease or toxicity warranting discontinuation, he was con-
sidered evaluable for the assessment of DLTs.
The second three eligible subjects were assigned to 
cohort no. 2; 120  mg IP BC-819 weekly for 3 weeks, 4 
weeks rest, then if possible repeat for one additional course, 
and the last three eligible subjects were assigned to cohort 
no. 3 (240 mg IP BC-819 weekly for 3 weeks, 4 weeks rest, 
then if possible repeat for one additional course). The 120 
and 240 mg cohorts adhered to the revised protocol.
As this was a multi-site study, dose escalation and 
enrollment were carefully coordinated between the study 
sites.
Potential study subjects included those with a histologi-
cal advanced stage recurrent ovarian cancer or primary per-
itoneal carcinoma who had either platinum-refractory dis-
ease or platinum-resistant recurrent disease.
Patients also had a Karnofsky performance status of 
≥70% with acceptable hematopoietic parameters, liver and 
renal function tests. A minimum of 30 days from the last 
active treatment was required before screening. Patients 
agreed to refrain from any concurrent chemotherapy, hor-
monal therapy, radiotherapy, immunotherapy or any other 
type of therapy for the treatment of cancer while on this 
protocol.
AEs evaluation
AEs included events reported by the subject, as well as 
clinically significant abnormal findings on clinical exami-
nation or laboratory evaluation. A new illness, symptom, 
sign or clinically significant clinical laboratory abnormality 
or worsening of a pre-existing condition or abnormality was 
considered an AE. In addition, abnormal laboratory values 
that met the criteria for an AE in accordance with the Com-
mon Terminology Criteria for Adverse Events (CTCAE), 
even if not considered clinically significant were reported 
as an AE. The CTCAE dictated also the severity grading of 
each AE. Stable chronic conditions, such as arthritis, which 
were present prior to enrollment and did not worsen, were 
not considered AEs.
Events were regarded generally “related” to BC-819 in 
case their time relationship to BC-819 treatment was not 
incompatible or making a casual connection improbable.
Statistical analysis
An analysis of the study data was performed when all of 
the subjects completed the study through at least week 4. 
The intention-to-treat and safety population were defined 
as all subjects who received the first intraperitoneal admin-
istration of the investigational product. The per protocol 
population included subjects who met the study inclusion 
and exclusion criteria, received all three study treatments 
with the investigational product (i.e., a complete treatment 
course) and had a follow-up disease assessment to examine 
the tumor response. Descriptive statistics for continuous 
variables, including the median and range, and for categori-
cal variables, including the count and percent, were used to 
describe the study data.
Results
A total of 14 Caucasian female subjects fulfilled the inclu-
sion criteria and enrolled into the study. Baseline char-
acteristics of the patients participating in the study are 
shown in Table  1: the mean age of the study population 
was 59.6 ± 9.8 years (range 38.0–75.0 years). All 14 sub-
jects had stage 3-C ovarian cancer when first diagnosed. 
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The mean and median times from disease diagnosis were 
3.2 ± 2.1 years and 2.5 years (range 0.8–7.1 years), respec-
tively. All subjects were heavily pretreated with chemother-
apy prior to enrollment (mean of 4 courses, range 1–10).
Of the 14 subjects who entered this study 8 subjects were 
enrolled into the 60  mg cohort, 3 subjects to the 120  mg 
cohort and 3 subjects to the 240 mg cohort (Table 2).
Of the 8 subjects enrolled into the 60 mg cohort, 2 sub-
jects completed the study, while 5 subjects withdrew pre-
maturely due to overall clinical deterioration (2 patients) or 
requested to withdraw prematurely (3 patients, of them one 
had also a serious infection and overall clinical deteriora-
tion) and one subject discontinued due to tumor progres-
sion per CT, clinical assessment and CA-125 elevation. Of 
the 3 subjects who were enrolled into the 120 mg cohort, 
1 subject completed the study and 2 withdrew prematurely 
due to overall clinical deterioration, concurrent illness, and 
disease progression. All three subjects enrolled into the 
240 mg cohort withdrew prematurely from the study due to 
overall clinical deterioration and disease progression.
Exposure to treatment
The maximal exposure possible for each subject was 6–9 
absolute doses of BC-819 60  mg (2–3 courses of 1 infu-
sion/week for 3 weeks). On average, the patients in the 
60  mg cohort were exposed to 270 ± 126  mg of BC-819, 
the patients in the 120  mg cohort were exposed to 
480 ± 204  mg of BC-819, and the patients in the 240  mg 
cohort were exposed to 720 ± 0.0 mg of BC-819.
Pharmacokinetics evaluation during treatment
There was a high variability in systemic (venous) PK 
parameters among patients, and plasma exposure increases 
measured by  Cmax (maximal concentration) and  AUCinf the 
calculated integral of the concentration–time curve, extrap-
olated to infinity were not proportional with dose.
Cmax and  AUCinf were higher in the 120 mg cohort than 
those observed in the 60  mg but also higher than those 
observed in the 240 mg cohort (Fig. 1). This may indicate 
altered absorption from the peritoneum due to the disease. 
Two peaks of plasmid were observed in the blood in 8/11 
of the patients. The first peak was observed 2–8  h after 
BC-819 administration, and the second peak was observed 
6–48  h after plasmid administration. The peaks can be 
explained by the fact that some of the plasmid may be 
transferred to the bloodstream from the peritoneum, which 
might be indicated by the first peak, and then transferred 
through the lymphatic system into the venous bloodstream, 
which might be represented by the later second peak in the 
graphs [23]. Plasmid plasma levels remained quantifiable 
for up to 48 h in all cohorts (last PK measurement). Termi-
nal elimination half-life was proportional with dose.
Table 1  Baseline 
characteristics of the study 
population
Parameter BC-819
60 mg (N = 8)
BC-819
120 mg (N = 3)
BC-819
240 mg (N = 3)
All (N = 14)
Mean age (years) ± SD 60.9 ± 12.0 61.3 ± 3.1 (3) 54.3 ± 7.6 59.6 ± 9.8
Mean height (cm) ± SD 158.6 ± 7.4 166.7 ± 1.5 157.3 ± 6.1 160.1 ± 7.0
Mean weight (kg) ± SD 71.4 ± 11.4 69.3 ± 5.8 62.9 ± 22.0 69.1 ± 12.7
Karnofsky performance 
status score ± SD
83.8 ± 7.4 80.0 ± 0.0 93.3 ± 5.8 85.0 ± 7.6
Ascites evaluation
 Grade 1 ascites, n (%) 0 (0) 0 (0) 0 (0) 0
 Grade 2 ascites, n (%) 1 (12.5) 2 (66.7) 2 (66.7) 5 (35.7)
 Grade 3 ascites, n (%) 5 (62.5) 1 (33.3) 0 6 (42.9)
 Without ascites 2 (25) 0 (0) 1 (33.3) 3 (21.4)
Table 2  Doses of BC-819 in each study cohort (PP population)
Cohort number Number of 
patients
Dose
1 6 Initial protocol 60 mg IP weekly for 3 weeks, 1 week rest, then repeat for 2 more courses (if possible)
2 Revised protocol 60 mg IP weekly for 3 weeks, 4 week rest, then repeat for 1 more course (if possible)
2 3 120 mg IP weekly for 3 weeks, 4 week rest, then repeat for 1 more course (if possible)
3 3 240 mg IP weekly for 3 weeks, 4 week rest, then repeat for 1 more course (if possible)
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The PK parameters for ascites fluid cells and for ascites 
fluid supernatant are summarized in Tables 3 and 4, respec-
tively, and the average ascites supernatant PK profiles for 
each dose are presented in Fig. 2.
After a single IP dose of BC-819, plasmid levels were 
still detectable in all cohorts after 48 h (in one subject in 
the 60 mg cohort, plasmid levels were still detectable after 
1 week). No dose proportionality in PK parameters could 
be detected due to high variability in PK parameters among 
patients.
In ascites fluid supernatant, the mean PK parameters 
of the 240 mg cohort were higher than those of the other 
cohorts, while in the blood these parameters were lower 
than those of the 120  mg cohort, indicating a different 
behavior in both compartments.
For mean number of copies of plasmid in ascites fluid 
cells, mean AUClast (the calculated integral of the con-
centration–time curve, from time 0 to last measurable con-
centration) is based on three patients and mean AUCinf is 
based on two patients only, as one patient had no AUCinf 
estimation. This patient had an extremely high plasmid 
count per 0.1  µg cellular DNA, and the level went up 
at 48  h, making it impossible to calculate a T1/2 for that 
patient and skewing the AUC for that cohort.
Adverse events (AE)
All 14 treated subjects reported a total of 148 AEs during 
the study. Of these, 99 AEs occurred in the 60 mg cohort, 
28 AEs in the 120 mg cohort, and 21 in the 240 mg cohort. 
Five possibly drug-related AEs were reported: 4 in the 
60  mg cohort and 1 in the 120  mg cohort (Table  5). No 
drug-related AEs were reported in the 240 mg cohort (all 
possibly drug-related AEs were grade 1 or 2). There was 
not a dominant AE which was related to one of the essen-
tial body systems.
Fifteen (15) treatment-emergent SAEs were reported 
in 7 treated patients. Of these, 12 SAEs were reported by 











Fig. 1  Mean copies/µl blood ± SE by treatment and time point
Table 3  Summary of main PK 
parameters by treatment in the 
















Cmax (copies/μL) 6.32E8 ± 7.49E8 428E8 ± 738E8 9.37E9 ± 116E8
Tmax (h) 12.8 ± 9.3 20.0 ± 24.2 6.0 ± 0.0
T 1/2 (h) 10.0 ± 6.9 13.2 ± 5.3 (n = 2) 6.4 ± 0.7
AUC last (copies/µl × h) 129E8 ± 179E8 517E9 ± 887E9 122E9 ± 154E9
AUC inf (copies/µl × h) 137E8 ± 18E9 5.05E9* ± 5.78E9 (n = 2) 123E9 ± 155E9
Table 4  Summary of main PK 














Cmax (copies/µL) 2.65E9 ± 3.94E9 1.6E9 ± 1.52E9 108E8 ± 3.14E9
Tmax (h) 33.0 ± 55.3 12.0 ± 10.4 6.0 ± 0.0
T 1/2 (h) 11.5 ± 6.7 (N = 4) 60.7 ± 71.3 15.6 ± 6.5
AUC last (copies/µl × h) 568E8 ± 114E9 (N = 7) 45E9 ± 47E9 301E9 ± 518E8
AUC inf (copies/µl × hours) 105E9 ± 174E9(N = 4) 66.3E9 ± 73.8E9 339E9 ± 193E8
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6 patients in the 60 mg cohort, and 3 were reported by 1 
patient in the 120  mg cohort. None of the SAEs were 
related to the study drug.
The incidence of AEs occurring in two or more 
patients is shown in Table 6. The most common adverse 
events reported were vomiting and a decrease in cal-
cium blood levels (in 50% of all patients), asthenia and 
activated partial thromboplastin time prolonged (42.9% 
each), and blood albumin decreased (35.7%). All 14 
(100%) patients reported laboratory AEs. General disor-
ders and administration site conditions were reported by 
10 patients (71.4%) and gastrointestinal disorders were 
reported by 9 patients (64.3%). In general, there was no 
evidence of a dose–response effect for frequency of indi-
vidual adverse events. The only adverse events occurring 
more frequently in the 240  mg group than in the other 
two treatment groups were [increased prothrombin time]/
[international normalized ratio] and decreased white 
blood cell count.
Thirteen (13) grade 3 AEs were reported during the 
study; 9 in the 60 mg cohort and 4 in the 120 mg cohort. 
One grade 4 AE (pulmonary embolism) was reported in 
the 120  mg cohort. No grade 3 or 4 AEs were reported 
by more than one patient, and none were reported in the 
240 mg cohort. None of the grade 3 or 4 AEs were con-
sidered related to the study drug (Table 7).
Response to treatment
The efficacy endpoints of the study were ascites response, 
solid measurable disease, survival and quality of life. 
Although serum was collected for quantitative measure-
ment of CA-125 (at screening and in the final week of 
every treatment course follow-up), the fact that this mark-
er’s levels may rise when injecting into the peritoneum 
[24], disqualified this measure as part of the tumor response 
measurements.
Ascites response was assessed by ultrasound and by 
numbers and volumes of paracenteses at various times dur-
ing treatment. The best ascites-related response that was 
observed during the study was stable disease with persis-
tence of ascites (i.e., incomplete response/stable disease).
Response outcomes were applied according to RECIST 
criteria for solid tumors [13]. The best overall response 
for solid tumor masses was stable disease i.e., insufficient 
shrinkage to qualify for partial response (at least 30% 
decreased in the longest diameter) and insufficient increase 
to qualify for progressive disease (at least a 20% increase in 
the longest diameter of the target lesion).
Table  8 shows the best response (measured at least 6 
weeks after the start of treatment) by treatment group, for 
solid tumor masses. Overall, 4 patients (31%) had stable 
disease at the first assessment. There were no complete or 
partial responses.
Overall survival, defined as the time from the start of 
treatment until the subject died, and estimated by Kaplan 
Meier curves for the intent to treat (ITT) (Fig. 3) and for 
the per protocol (PP) population, is presented in Table 9.























Fig. 2  Mean copies/[µl of fluid] ±SE by treatment and time point in 
ascites fluid supernatant





Patients, N (%) Events, N Patients, N (%) Events, N Patients, N (%) Events, N
Cardiac disorders
 Dizziness 1 (12.5) 1 1 (7.1) 1
Gastrointestinal disorders
 Nausea 1 (12.5) 1 1 (7.1) 1
General disorders and administration site conditions
 Asthenia 1 (33.3) 1 1 (7.1) 1
 Pyrexia 1 (12.5) 1 1 (7.1) 1
Skin and subcutaneous tissue disorders
 Erythema 1 (12.5) 1 1 (7.1) 1
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Survival data for this cohort was denoted by median 
overall survival in the ITT population which was estimated 
at 4.2+ months (range 1.6–16.7 months), and 5.3+ months 
in the PP population (range 3.1–16.7 months). There 
appears to be a dose–response relationship for survival 
(Fig. 3) with median survival 3.2, 5.3 and 6.5 months for 
the 60, 120 and 240  mg ITT cohorts, respectively. These 
observations should be evaluated with caution due to the 
small cohort sizes, differences with regard to overall perfor-
mance status and the possibility of selection bias towards 
healthier patients as the trial progressed.
Quality of life
Composite scores and subscale scores from the FACT-O 
were used to assess QoL outcomes. Although assessment 
of QoL showed an overall worsening for the whole patient 
population treated (i.e., decrease in total score), assessment 
of FACT-O composite scores by visit showed an improve-
ment in QoL of the 60 mg cohort on visits 6, 7 and 11 (ITT 
population) and on visits 5, 6, 7 and 11 (PP population); 
an improvement in QoL on visits 4, 8, 11, 12 and 13 in the 
120 mg cohort (PP and ITT populations); and an increase 
in total score on visit 4 in the 240 mg cohort (PP and ITT 
populations).
Table 6  Summary of adverse 
events occurring in two or more 
patients in any cohort








Cardiac disorders 1 (12.5) 2 (66.7) 3 (21.4)
Gastrointestinal disorders 6 (75.0) 2 (66.7) 1 (33.3) 9 (64.3)
 Constipation 2 (25.0) – 1 (33.3) 3 (21.4)
 Diarrhea 3 (37.5) 1 (33.3) – 4 (28.6)
 Dyspepsia 1 (12.5) – 1 (33.3) 2 (14.3)
 Vomiting 6 (75.0) 1 (33.3) – 7 (50.0)
General disorders and administration site conditions 5 (62.5) 3 (100.0) 2 (66.7) 10 (71.4)
 Asthenia 4 (50.0) 2 (66.7) – 6 (42.9)
 General physical health deterioration 2 (25.0) – – 2 (14.3)
Infections and infestations 1 (12.5) 1 (33.3) 2 (14.3)
Injury, poisoning and procedural complications 3 (37.5) 3 (21.4)
 Fall 2 (25.0) – – 2 (14.3)
Investigations 8 (100) 3 (100) 3 (100) 14 (100)
 Activated partial thromboplastin time prolonged 4 (50.0) 1 (33.3) 1 (33.3) 6 (42.9)
 Alanine aminotransferase increased 3 (37.5) – – 3 (21.4)
 Aspartate aminotransferase increased 4 (50.0) – – 4 (28.6)
 Blood albumin decreased 2 (25.0) 2 (66.7) 1 (33.3) 5 (35.7)
 Blood calcium decreased 3 (37.5) 3 (100.0) 1 (33.3) 7 (50.0)
 Blood potassium increased 3 (37.5) 1 (33.3) – 4 (28.6)
 Hemoglobin decreased 3 (37.5) – 1 (33.3) 4 (28.6)
 International normalized ratio increased 2 (25.0) – 2 (66.7) 4 (28.6)
 White blood cell count decreased – – 2 (66.7) 2 (14.3)
Metabolism and nutrition disorders 2 (25.0) 1 (33.3) 3 (21.4)
 Hypocalcemia 2 (25.0) 1 (33.3) – 3 (21.4)
Nervous system disorders 2 (25.0) 1 (33.3) 3 (21.4)
 Headache 2 (25.0) – 1 (33.3) 3 (21.4)
Renal and urinary disorders 4 (50.0) 1 (33.3) 5 (35.7)
 Urinary tract infection 3 (37.5) – – 3 (21.4)
Respiratory, thoracic and mediastinal disorders 1 (12.5) 2 (66.7) 3 (21.4)
 Dyspnoea 1 (12.5) 2 (66.7) – 3 (21.4)
Skin and subcutaneous tissue disorders 2 (25.0) 1 (33.3) 3 (21.4)
 Erythema 1 (12.5) 1 (33.3) – 2 (14.3)
 Rash 1 (12.5) 1 (33.3) – 2 (14.3)
Vascular disorders 1 (12.5) 1 (33.3) 2 (14.3)
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Due to the small number of subjects in each cohort, the 
change in QoL scores from baseline could not be assessed 
statistically.
Pain scale scores
An increase in pain scale scores was observed in the 60 mg 
cohort on visits 4, 10, 11, 14 and 15. A decrease in pain 
scale scores was observed in the 60 mg cohort on visits 1 
and 5, and in both the 120 and the 240 mg cohorts on visit 
5.
Discussion
The aim of this study was to assess the pharmacokinet-
ics, and preliminary efficacy of BC-819 administered IP in 
subjects with recurrent, platinum-resistant advanced stage 
heavily pretreated ovarian cancer or primary peritoneal 
carcinoma.
Fourteen patients, who were heavily pretreated with 
chemotherapy prior to enrollment, participated in the study.
Three dose levels of BC-819 were assessed: 60, 120, and 
240 mg. In all dosages, plasmids were detected in blood as 
well as in the cellular and fluid fractions of the ascites 2 
Table 7  Display of grade 3 and 4 AEs by MedDRA® Categories





Patients, N (%) Events, N Patients, N (%) Events, N Patients, N (%) Events, N
Blood and lymphatic system disorder
 Anemia 3 1 (12.5) 1 1 (7.1) 1
Gastrointestinal disorders
 Abdominal pain 3 1 (12.5) 2 1 (7.1) 2
 Vomiting 3 1 (12.5) 1 1 (7.1) 1
General disorders and administration site conditions
 Asthenia 3 1 (12.5) 1 1 (7.1) 1
 Device occlusion 3 1 (33.3) 1 1 (7.1) 1
 General physical health deterioration 3 1 (12.5) 1 1 (7.1) 1
Injury, poisoning and procedural complications
 Procedural pain 3 1 (12.5) 1 1 (7.1) 1
Investigations
 Blood calcium decreased 3 1 (33.3) 1 1 (7.1) 1
 Hemoglobin decreased 3 1 (12.5) 1 1 (7.1) 1
 Hepatic enzyme increased 3 1 (12.5) 1 1 (7.1) 1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
 Neoplasm malignant 3 1 (12.5) 1 1 (7.1) 1
Respiratory, thoracic and mediastinal disorders
 Dyspnoea 3 1 (33.3) 1 1 (7.1) 1
 Vascular disorders
 Pulmonary embolism 4 1 (33.3) 1 1 (7.1) 1
Table 8  Tumor response in the ITT (intent to treat) population
*One patient was not assessed for tumor response
BC-819 dose, mg All patients
60 120 240
N 7 (87.5%)* 3 (100) 3 (100) 13 (92.9)*
Stable disease 2 (29) 2 (67) 4 (31)
Progressive disease 2 (29) 1 (33) 3 (100) 6 (46)
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Fig. 3  Kaplan–Meier curve for survival—ITT population
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days post-administration and in some cases even more. We 
have already shown elsewhere that BC-819 administration 
IP to ovarian cancer patient resulted in RNA presence of 
DTA in ascites cells [21]. The primary objectives of this 
study were to identify any dose-limiting toxicity and to 
determine the maximal tolerated dose of BC-819. During 
the study no dose-limiting toxicity was observed and there-
fore no maximal tolerated dose could be established. The 
highest dose administered was 240  mg of BC-819 which 
can therefore be considered as safe and well tolerated.
The majority of AEs reported were considered to be 
related to the patients’ underlying advanced ovarian can-
cer, and/or general clinical deterioration due to disease 
progression. Only five grade 1 and 2 AEs were consid-
ered to be possibly related to BC-819 and no serious AEs 
were considered to be related to the investigational drug. 
One serious AE was considered related to the study pro-
cedure. These findings suggest that BC-819 is a safe and 
well-tolerated novel technology for patients with platinum-
resistant advanced stage heavily pretreated ovarian cancer 
or primary peritoneal carcinoma.
The secondary objectives of the study included the 
determination of the overall survival distribution. Overall 
survival seen in this study is in accordance with other stud-
ies which reported a range of 6.3–15 months for median 
overall survival in heavily pretreated patients with recurrent 
platinum-resistant ovarian cancer [25–30].
The best ascites-related response that was observed dur-
ing the study was stable disease with persistence of ascites. 
The best response for solid tumors was stable disease (i.e., 
insufficient shrinkage to qualify for partial response and 
insufficient increase to qualify for progressive disease). 
These findings may suggest a potential response of less 
advanced ovarian/peritoneal tumors to BC-819.
PK analysis indicated that BC-819 remains in ascites 
fluid cells and supernatant for at least 48 h. It is absorbed 
into the blood and remains quantifiable for at least 48  h 
(the last PK measurement). Two peaks of plasmid in the 
blood were observed in 8 of the patients; this may indicate 
that some of the plasmid is transferred to the bloodstream 
from the peritoneum (first peak), and then it is transferred 
through the lymphatic system into the venous bloodstream 
(second peak). A similar pattern was observed in the com-
passionate use ovarian cancer patient treated with BC-819. 
As there was high variability among patients in the PK 
parameters measured, no conclusions can be made regard-
ing the relationship between drug dose and PK of BC-819.
Determination of the QoL of the subjects receiving 
BC-819
QoL, as assessed by the FACT-O scale, showed overall 
worsening of the QoL score; however, improvement in QoL 
was observed on some study visits. The change in QoL 
could not be evaluated statistically due to the small number 
of subjects in each cohort. Since all participating patients in 
the trial had ovarian or peritoneal tumors expressing H19, 
the question arises: why some tumors, expressing H19, did 
not respond?
The preliminary results of this phase1/2 study can be 
explained by several mechanisms:
1. Patients with more advanced or aggressive disease 
have a tendency for being “Non-responding” patients 
suggesting that in early disease the BC-819 will pro-
duce a better tumor response rate.
2. There could be kinetic obstacle that prohibits long 
enough exposure of malignant and premalignant cells 
to the plasmid.
3. In pre-heavily treated tumor cells the H19 gene is not 
active, thus no toxin is released in the tumor cells, sug-
gesting the failure of BC-819 in ablating the tumor 
marker.
In the era where intraperitoneal chemotherapy and bio-
logical treatments for advanced stage ovarian and perito-
neal carcinoma are suggesting a significant advantage in 
the disease-free interval and in overall survival, the devel-
opment of a biological anti-tumor DNA-based therapy and 
the use of a combination of biological agents with conven-
tional chemotherapy with an IV and IP approach may offer 
a promising advantage in the response rate or in the overall 
survival of these patients.
In this study a tumor-selective promoter was used in 
conjunction with a cytotoxic gene to achieve targeted tumor 
cell destruction. The plasmid BC-819 has advantages over 
viral vectors including lack of immunogenicity and cyto-
toxicity allowing repeated treatments.
Taken together, the data of this study suggest that:
Table 9  Overall survival in the ITT and the PP populations




60 mg N 8 5
Median (range) 3.2+ (1.6–16.7+) 3.9+ (3.1–16.7+)
120 mg N 3 3
Median (range) 5.3 (3.2–8.3) 5.3 (3.2–8.3)
240 N 3 3
Median (range) 6.5+ (4.5–7.4+) 6.5+ (4.5–7.4+)
All N 14 11
Median (range) 4.2+ (1.6–16.7+) 5.3+ (3.1–16.7+)
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1. BC-819 can be considered safe and well tolerated in 
intraperitoneal doses up to 240 mg.
2. BC-819 given locally in combination with systemic 
chemotherapy may provide additional therapeutic ben-
efit for the treatment of ovarian or peritoneal cancer.
3. The hybridization of intraperitoneal chemotherapy 
with the biological treatment of BC-819 should be fur-
ther evaluated in phase 2 and 3 studies.
This study confirmed the excellent safety profile of 
BC-819 with a low rate of adverse effects and no grade 3 
events attributable to the agent. Therefore it may be con-
cluded that BC-819 is safe to use intraperitoneally in 
patients with ovarian, peritoneal and tubal cancer .Since 
the study is limited by the small number of patients, future 
studies should include larger cohorts, higher doses, longer 
periods of treatment and combination with other systemi-
cally administered drugs.
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